Serology tests. SARS-CoV-2 is the virus that causes COVID-19. The Serology test detects antibodies against SARS-CoV-2 in a blood sample taken from the test subject. The blood sample may be whole blood, serum or plasma. (In the case of coagulated whole blood, serum, or plasma the sample must be centrifuged.) Antibodies are produced by an adaptive immune response against the virus. Immune responses to viral infection may differ from patient to patient, take time to develop, and usually proceed in a phased manner.
Immune responses to SARS-CoV-2 may differ significantly from the usual immune response to viral pathogens. Initial immune responses to viral pathogens often produce a IgM antibodies soon after the infection, which lasts for a short period. Later in the course of a typical infection IgG antibodies are usually produced and these IgG antibodies may be detectable for months or years after infection. Detection of antibodies in a test subject’s blood are an indicator of past or current exposure to SARS-CoV-2, but do not necessarily indicate current infection. It is not currently known whether antibodies to SARS-CoV-2 provide full or partial immunity to the virus, and if so, for how long.
- Patel, et al., “Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of Diagnostic Testing for SARS–CoV-2/COVID-19”, https://doi.org/10.1128/MBIO.00722-20.
- Li, et al., “Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis”, https://doi.org/10.1002/jmv.25727.
- Lee, et al., “A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic”, https://doi.org/10.1016/j.jmii.2020.03.003.
- To, et al., “Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study”, https://doi.org/10.1016/S1473-3099(20)30196-1.
- Zhao, et al., “Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”, https://doi.org/10.1093/cid/ciaa344.
- Lassaunière, et al., “Evaluation of nine commercial SARS-CoV-2 immunoassays”, https://doi.org/10.1101/2020.04.09.20056325.
- Padoan, et al., “Analytical performances of a chemiluminescence immunoassay for SARS-CoV-IgM/IgG and antibody kinetics”, https://doi.org/10.1515/cclm-2020-0443.
- Jin, et al., “Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019”, https://doi.org/10.1016/j.ijid.2020.03.065.
- Guo, et al., “Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)”, https://doi.org/10.1093/cid/ciaa310.
- Xiang, et al., “Antibody Detection and Dynamic Characteristics in Patients with COVID-19”, https://doi.org/10.1093/cid/ciaa461.
- Wang, et al., “Long-term Coexistence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with Antibody Response in Coronavirus Disease 2019 (COVID-19) Patients”, https://doi.org/10.1101/2020.04.13.20040980.